TAILIEUCHUNG - Ebook HIV-Associated hematological malignancies (E): Part 2

(BQ) Part 2 book “HIV-associated hematological malignancies” has contents: HIV and indolent lymphoma, HIV-Associated hodgkin lymphoma, acute lymphoblastic leukemia, autologous stem cell transplantation, allogeneic stem cell transplantation, allogeneic stem cell transplantation, and other contents. | 9 HIV-Associated Hodgkin Lymphoma Marcus Hentrich, Michele Spina, and Silvia Montoto Contents Introduction Epidemiology . CD4 T-Cell Counts and Risk of HIV-HL . Pathology . Management. Clinical Presentation and Diagnosis Prognostic Factors Primary Chemotherapy Relapsed and Resistant Disease . Future Directions . References . 120 120 121 121 123 123 124 124 127 127 128 M. Hentrich, MD (*) Department of Hematology and Oncology, Red Cross Hospital, University of Munich, Munich, Germany e-mail: M. Spina Division of Medical Oncology A, National Cancer Institute, Aviano, Italy e-mail: mspina@ S. Montoto, MD Centre for Haemato-Oncology, St Bartholomew’s Hospital, Barts Cancer Institute, Queen Mary University of London, London, UK e-mail: © Springer International Publishing Switzerland 2016 M. Hentrich, . Barta (eds.), .

• Y khoa - Dược
• HIV associated hematological malignancies
• Associated hematological malignancies
• Indolent lymphoma
• Associated hodgkin lymphoma
• Acute lymphoblastic leukemia
• Relapse analysis
• Childhood acute lymphoblastic leukemia
• Hue Central Hospital
• Pediatrics oncology
• BMC Pediatrics
• Final height
• Body mass index
• Childhood acute lymphoblastic leukemia treated
• Relapse childhood
• Developing countries
• BMC Cancer
• Extramedullary relapse
• Case report
• Acute T lymphoblastic leukemia
• Hematopoietic stem cell transplantation
• Therapy outcomes
• B cell acute lymphoblastic leukemia
• Multiplex RQ PCR
• Bone Sialoprotein 1
• CD44 variant 6
• Receptor CD44 Variant 6
• Role of bone sialoprotein 1
• A20 on glucose dependent cell migration in acute lymphoblastic leukemia
• Peripheral blood mononuclear cells
• Determined by quantitative RT PCR
• Gene expression profile
• Lymphoblastic Leukemia
• Clustering Analysis
• Epidemiological Evidence
• Childhood Acute Leukemia
• Analytical validation
• Multiple myeloma
• Chronic lymphocytic leukemia
• Measurable residual disease
• Minimal residual disease
• Tyrosine kinase inhibitor
• Chronic myeloid leukemia
• Kinase inhibitors
• Donor leukemia
• Whole exome sequencing
• Familial acute lymphoblastic leukemia
• Childhood leukemia predisposition
• Fanconi anemia genes
• Hematopoietic dysfunction
• Pediatric leukemia
• Congenital acute lymphoblastic leukemia
• Exome sequencing
• DNA repair
• Genome Biology
• Adult acute lymphoblastic leukemia
• T ALL evolution under therapy
• Evolution of leukemia relapse
• ALL relapse
• Acute myeloid leukemia
• Long noncoding RNA
• C Myc
• Tumor development
• Jurkat cell line
• GC regulation
• Cell cycle arrest
• Lymphoid cells
• GC induced candidate genes
• Immunologic markers
• Blood transfusion
• MLL AF4 fusion gene
• BCR ABL1 fusion gene group
• Overall survival
• Rapid early response
• Slow early response
• Event free survival
• Low molecular weight heparin
• Venous thromboembolic disease
• Historic control cohorts
• T cell acute lymphoblastic leukemia
• Prednisone response
• BMC Biotechnology
• CRISPR Cas9
• Genome editing
• Future clinical trials
• Molecular pathogenesis
• Childhood malignancy
• Ras pathway
• Risk stratification
• Characteristics of immunologic markers
• Pediatric acute lymphoblastic leukemia
• Genetic mutation
• National institute
• Hematology and blood transfusion
• Early mortality
• Childhood overweight
• Centers for Disease Control and Prevention
• Reaching epidemic